Glenmark Pharmaceuticals and Canadian pharma company SaNOtize Research & Development Corp. have launched the latter’s Nitric Oxide Nasal Spray under the brand name FabiSpray in India for the treatment of adults with Covid-19, who have a high risk of disease progression

Earlier, Glenmark Pharmaceuticals had secured manufacturing and marketing approval from the Drugs Controller General of India (DCGI) for Nitric Oxide Nasal Spray under an accelerated approval process.

Nitric Oxide Nasal Spray is designed to eliminate the virus causing Covid-19 in the upper airways. It is said to have proven anti-microbial properties with a direct virucidal effect on the SARS-CoV-2 virus.

When sprayed over nasal mucosa, FabiSpray works as a physical and chemical barrier against the virus, thereby stopping it from incubating and spreading to the lungs.

Robert Crockart — Chief Commercial Officer at Glenmark Pharmaceuticals said: “As a leading pharmaceutical player, it is important that we are an integral part of India’s fight against the COVID-19 pandemic. We are happy to receive regulatory approval for Nitric Oxide Nasal Spray (FabiSpray) and launch it in partnership with SaNOtize.

This reaffirms our commitment of providing yet another safe and effective antiviral treatment for COVID-19, and we are confident it will offer patients a much needed and timely therapy option.”

  COVID-19, FabiSpray, Glenmark Pharmaceuticals, India, Nasal spray, Nitric Oxide Nasal Spray, Robert Crockart, SaNOtize Research & Development, SARS-CoV-2, SARS-CoV-2 virus